CAR cell therapy trial for multiple myeloma and related cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase (Phase 1) trial tests a lab-made immune-cell treatment that targets two markers, BCMA and CD19, in people whose cancer has not responded to standard options. It’s meant to see if the treatment is safe and how well it can work in these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent to join the study.
- You have a diagnosis of multiple myeloma or plasmacytoid lymphoma based on the WHO 2008 criteria.
- Your cancer has tried and used up standard treatments, with no good remaining options.
- Any immune-suppressing medicines or steroid pills must have been stopped for more than 1 week before starting.
- If you are able to become pregnant: you must not be pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and destroy myeloma cells that have a protein called BCMA. It is for people whose multiple myeloma has come back or hasn't responded to other treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.